Regeneron Pharmaceuticals, Inc. (REGN) Stock Rating Lowered by Barclays PLC

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was downgraded by equities research analysts at Barclays PLC from an “equal weight” rating to an “underweight” rating in a report issued on Friday.

A number of other brokerages also recently weighed in on REGN. Leerink Swann restated an “outperform” rating and issued a $573.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 22nd. Raymond James Financial, Inc. restated an “outperform” rating and issued a $547.00 target price (up previously from $475.00) on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 22nd. Bank of America Corporation restated a “buy” rating and issued a $593.00 target price (up previously from $589.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, July 21st. BMO Capital Markets reiterated a “market perform” rating and issued a $484.00 price objective (up previously from $421.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, July 21st. Finally, Sanford C. Bernstein downgraded Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating and upped their price objective for the company from $410.00 to $480.00 in a research note on Monday, June 26th. They noted that the move was a valuation call. Four investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Regeneron Pharmaceuticals currently has an average rating of “Hold” and an average target price of $489.92.

Shares of Regeneron Pharmaceuticals (NASDAQ REGN) opened at 440.94 on Friday. The stock has a 50 day moving average price of $452.90 and a 200-day moving average price of $456.40. The firm has a market capitalization of $46.75 billion, a PE ratio of 44.24 and a beta of 1.62. Regeneron Pharmaceuticals has a 52-week low of $325.35 and a 52-week high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, topping analysts’ consensus estimates of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm had revenue of $1.47 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter in the previous year, the business earned $2.82 EPS. The company’s revenue was up 21.2% compared to the same quarter last year. Equities analysts forecast that Regeneron Pharmaceuticals will post $14.94 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://ledgergazette.com/2017/10/20/regeneron-pharmaceuticals-inc-regn-stock-rating-lowered-by-barclays-plc.html.

In related news, CFO Robert E. Landry sold 189 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total value of $94,700.34. Following the transaction, the chief financial officer now owns 10,099 shares of the company’s stock, valued at $5,060,204.94. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Michael S. Brown sold 1,500 shares of the stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $475.00, for a total value of $712,500.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 89,468 shares of company stock worth $42,312,448. Insiders own 10.80% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Intl Fcstone Inc. bought a new position in Regeneron Pharmaceuticals in the second quarter valued at $346,000. Lord Abbett & CO. LLC bought a new position in Regeneron Pharmaceuticals in the second quarter valued at $51,931,000. Toronto Dominion Bank increased its stake in Regeneron Pharmaceuticals by 25.8% in the second quarter. Toronto Dominion Bank now owns 25,835 shares of the biopharmaceutical company’s stock valued at $12,686,000 after acquiring an additional 5,295 shares during the last quarter. WINTON GROUP Ltd bought a new position in Regeneron Pharmaceuticals in the seco

A number of other brokerages also recently weighed in on REGN. Leerink Swann restated an “outperform” rating and issued a $573.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 22nd. Raymond James Financial, Inc. restated an “outperform” rating and issued a $547.00 target price (up previously from $475.00) on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 22nd. Bank of America Corporation restated a “buy” rating and issued a $593.00 target price (up previously from $589.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, July 21st. BMO Capital Markets reiterated a “market perform” rating and issued a $484.00 price objective (up previously from $421.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, July 21st. Finally, Sanford C. Bernstein downgraded Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating and upped their price objective for the company from $410.00 to $480.00 in a research note on Monday, June 26th. They noted that the move was a valuation call. Four investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Regeneron Pharmaceuticals currently has an average rating of “Hold” and an average target price of $489.92.

Shares of Regeneron Pharmaceuticals (NASDAQ REGN) opened at 440.94 on Friday. The stock has a 50 day moving average price of $452.90 and a 200-day moving average price of $456.40. The firm has a market capitalization of $46.75 billion, a PE ratio of 44.24 and a beta of 1.62. Regeneron Pharmaceuticals has a 52-week low of $325.35 and a 52-week high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, topping analysts’ consensus estimates of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm had revenue of $1.47 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter in the previous year, the business earned $2.82 EPS. The company’s revenue was up 21.2% compared to the same quarter last year. Equities analysts forecast that Regeneron Pharmaceuticals will post $14.94 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://ledgergazette.com/2017/10/20/regeneron-pharmaceuticals-inc-regn-stock-rating-lowered-by-barclays-plc.html.

In related news, CFO Robert E. Landry sold 189 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total value of $94,700.34. Following the transaction, the chief financial officer now owns 10,099 shares of the company’s stock, valued at $5,060,204.94. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Michael S. Brown sold 1,500 shares of the stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $475.00, for a total value of $712,500.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 89,468 shares of company stock worth $42,312,448. Insiders own 10.80% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Intl Fcstone Inc. bought a new position in Regeneron Pharmaceuticals in the second quarter valued at $346,000. Lord Abbett & CO. LLC bought a new position in Regeneron Pharmaceuticals in the second quarter valued at $51,931,000. Toronto Dominion Bank increased its stake in Regeneron Pharmaceuticals by 25.8% in the second quarter. Toronto Dominion Bank now owns 25,835 shares of the biopharmaceutical company’s stock valued at $12,686,000 after acquiring an additional 5,295 shares during the last quarter. WINTON GROUP Ltd bought a new position in Regeneron Pharmaceuticals in the second quarter valued at $713,000. Finally, Public Employees Retirement System of Ohio increased its stake in Regeneron Pharmaceuticals by 1.6% in the second quarter. Public Employees Retirement System of Ohio now owns 54,288 shares of the biopharmaceutical company’s stock valued at $26,663,000 after acquiring an additional 867 shares during the last quarter. 67.40% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply